Testing a new immune therapy for early-stage type 1 diabetes

This trial is testing a medication called teplizumab to see if it can help slow down type 1 diabetes in its earliest stages. The study focuses on children and young adults (ages 1–34) who have been diagnosed with Stage 2 type 1 diabetes — a phase where the immune system is attacking insulin-producing cells but blood sugar control hasn't yet become severely abnormal. Researchers hope this treatment might preserve remaining insulin production and delay or prevent the need for insulin injections.

Type 1 diabetes develops gradually as the immune system mistakenly attacks the pancreas. If caught early enough — before most insulin-producing cells are destroyed — this medication might help stop that attack and protect the remaining healthy cells. This trial is exploring whether early treatment can make a real difference in how the disease progresses.